Among 379 953 participants (mean age, 56.2 [SD, 8.1] years; 44.6% men), 7396 (1.9%) had a Fibrosis‐4 index >2.67 at baseline. During a median follow‐up of 12.75 (interquartile range, 12.03–13.48) ...

Hepatic fibrosis is the common result of injury to the liver from a variety of damaging mechanisms, and the accurate assessment of the degree of fibrosis is clinically important. For many years ...

Shares of Akero Therapeutics AKRO skyrocketed 105.7% in a week after the company announced initial positive top line 96-week ...

After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...

Metabolic dysfunction-associated steatotic liver disease, or MASLD, is an umbrella term describing conditions related to a ...

Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...

(ETNB) stock jumped 40% Monday, stoked by positive data for Akero's (AKRO) drug efruxifermin in the treatment of compensated ...

Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

Our livers contain many different types of immune cells. New research by the team of Prof. Charlotte Scott (VIB-UGent Center ...

Dr Amir Khan has warned over a condition that affects one in five Brits - and can be caused by a range of factors with very ...

Data from 22 studies, encompassing 756,088 subjects, including 62,072 Hispanic adults, revealed striking findings. The pooled ...

"Now, most people will have no symptoms, and the diagnosis is often picked up through a random blood test or a scan. But ...